Lungenbeteiligung im Rahmen der IgG4-assoziierten Erkrankungen

V. S. Schäfer

doi:10.1055/s-0032-1312619

Aktuelle Rheumatologie, Table of Contents

Aktuelle Rheumatologie 2012; 37(05): 313-319
DOI: 10.1055/s-0032-1312619

Übersichtsarbeit

Lungenbeteiligung im Rahmen der IgG4-assoziierten Erkrankungen

Lung Involvement in IgG4-Related Systemic Disease

V. S. Schäfer

¹Asklepios Klinik Bad Abbach Rheumatologie und Klinische Immunologie, Bad Abbach

› Author Affiliations

Abstract

Zusammenfassung

Immunoglobulin G4-assoziierte Erkrankungen (IGAE) sind eine vor kurzem definierte und an Wichtigkeit zunehmende Entität. Sie charakterisiert sich durch die Bildung von inflammatorischen Reaktionen, reich an IgG4-positiven Plasmazellen, begleitet von einer Fibrosklerose und einer obliterativen Phlebitis. In der immunohistochemischen Färbung zeigen sich erhöhte IgG4-positive Zellen in den betroffenen Organen. Im Serum finden sich erhöhte IgG, sowie IgG4-Spiegel, welche der Erkrankung den Namen gaben. Die IGAE betreffen Patienten in den mittleren und älteren Jahren, mit einer männlichen Prädominanz. Der Prototyp ist die autoimmune Pankreatitis (AIP), dort wurde die Diagnose einer IGAE zum ersten Mal gestellt. Mögliche Manifestationen der IgG4-assoziierten Erkrankungen sind retroperitoneale Fibrose, Dakryoadenitis, Sialadenitis, Thyroiditis, Pneumonitis, Pankreatitis, sklerosierende Cholangitis, Nephritis, Otitis media, Aortitis, Periaortitis, Prostatitis und Hypophysitis [1] [2]. Nicht selten findet sich auch eine Beteiligung mehrerer Organsysteme beim gleichen Patienten. In der Lunge können das Parenchym, der Pleuraraum, das Mediastinum, sowie die Luftwege betroffen werden. Zur Diagnosesicherung ist eine Biopsie, vorzugsweise eine chirurgische Resektion, zwingend erforderlich. Eine PET/CT Untersuchung kann bei Patienten mit einer IGAE sinnvoll sein, um einen Überblick über den Organbefall zu bekommen, sowie um die beste Biopsieentnahmestelle zu lokalisieren. IGAE sprechen in der Regel gut auf die Behandlung mit Glukokortikoiden an, es kann jedoch unter einer Glukokorticoid-Monotherapie zu Rückfällen kommen. Unter der Behandlung mit Glukokortikoiden kommt es häufig zu einem Absinken der Serum IgG4-Spiegel. Es gibt wenige Veröffentlichungen, die den Gebrauch von pharmakologischen Substanzen außer Kortikosteroiden beschreiben. Eine adjunktive Therapie mit Bortezomib, sowie Cyclosporin könnte sich als vielversprechend erweisen. Bis jetzt wurde in der Literatur keine Spontanheilung der intrathorakalen IGAE beschrieben. Es gibt leider keine weiteren Information zu anderen Immunsuppressiva bei Lungenbefall im Rahmen einer IGAE, jedoch wurden Azathioprin, Mycophenolat, Methotrexat und Cyclophosphamid manchmal benutzt um einem Langzeitrückfall bei dem Befall von extrapulmonalen Organen vorzubeugen. Die Natur, sowie die Pathogenese der IGAE sind zum jetzigen Zeitpunkt weitestgehend unbekannt und bieten somit einen großen Forschungsbedarf.

Abstract

Immunoglobulin G4-related systemic disease (IRSD) is a recently defined and emerging entity characterized by a diffuse or mass forming inflammatory reaction, rich in IgG4-positive plasma cells, associated with fibrosclerosis and obliterative phlebitis. Affected organs are found to exibit an increased number of IgG4-positive cells. In the serum, raised IgG and IgG4-levels are found, which acts as a marker for this recently characterized entity. IRSD affects patients in midlle and older age, with a male predominance. The prototype of the disease is the autoimmune pancreatitis (AIP), being the first organ to be diagnosed with an IRSD. Possible manifestations of the IRSD are retroperitoneal fibrosis, dacryoadenitis, sialadenitis, thyroiditis, pneumonitis, pancreatitis, sclerosing cholangitis, nephritis, otitis media, aortitis, periaortitis, prostatitis, and hypophysitis. Often manifestations of several organs can be found in the same patient. In the lung, IRSD can affect the parenchyma, the pleura, the mediastinum as well as the airways. In order to diagnose an IRSD, a biopsy, preferably a surgical resection is necessary. Positron emission tomography with computer tomography (PET/CT) can provide an overview of the organs being involved, as well as localizing the best site for biopsy. IRSD normally responds well to glucocorticosteroids, nevertheless under glucocorticoid monotherapy a relapse can occur. During therapy with glucocorticosteroids, serum IgG4-levels decline. There are few reports, which describe the use of pharmacological substances other than corticosteroids. An adjunctive therapy with Bortezomib, as well as cyclosporine seems to be promising. Until now, no spontaneous healing of a intrathoracic IRSD was described. Unfortunately no further data about other immunosuppressants and lung involvement in IRSD are available, however azathioprin, mycophenolat, methotrexat and cyclophosphamide were sometimes used in order to prevent a longtime relapse in patients with extrapulmonary disease. However, the nature and pathogenesis of RSD are yet to be fully elucidated and provide immense scope for further research.

Schlüsselwörter

IgG4 assoziierte Erkrankungen - Pulmonale Infiltrate - Interstitielle Lungenerkrankung - Lymphadenopathie

Key words

IgG4 related systemic disease - Pulmonary infiltrates - Interstitial lung disease - Lymphadenopathy

Full Text

References

Literatur
1 Ebbo M, Grados A, Daniel L et al. IgG4-related systemic disease: emergence of a new systemic disease? Literature review. La Revue de medecine interne/fondee par la Societe nationale francaise de medecine interne 2012; 33: 23-34
2 Patel SM, Szostek JH. IgG4-related systemic disease in a Native American man. Intern Med 2011; 50: 931-934
3 Hamano H, Kawa S, Horiuchi A et al. High serum IgG4 concentrations in patients with sclerosing pancreatitis. The New England journal of medicine 2001; 344: 732-738
4 Takuma K, Kamisawa T, Igarashi Y. Autoimmune pancreatitis and IgG4-related sclerosing cholangitis. Current opinion in rheumatology 2011; 23: 80-87
5 Carruthers MN, Stone JH, Khosroshahi A. The latest on IgG4-RD: a rapidly emerging disease. Current opinion in rheumatology 2012; 24: 60-69
6 Dahlgren M, Khosroshahi A, Nielsen GP et al. Riedel’s thyroiditis and multifocal fibrosclerosis are part of the IgG4-related systemic disease spectrum. Arthritis care & research 2010; 62: 1312-1318
7 Khosroshahi A, Stone JH. A clinical overview of IgG4-related systemic disease. Current opinion in rheumatology 2011; 23: 57-66
8 Khosroshahi A, Stone JH. IgG4-related systemic disease: the age of discovery. Current opinion in rheumatology 2011; 23: 72-73
9 Zen Y, Nakanuma Y. IgG4-related disease: a cross-sectional study of 114 cases. The American journal of surgical pathology 2010; 34: 1812-1819
10 Kamisawa T, Okamoto A. IgG4-related sclerosing disease. World journal of gastroenterology: WJG 2008; 14: 3948-3955
11 Pickartz T, Mayerle J, Lerch MM. Autoimmune pancreatitis. Nature clinical practice Gastroenterology & hepatology 2007; 4: 314-323
12 Smyrk TC. Pathological features of IgG4-related sclerosing disease. Current opinion in rheumatology 2011; 23: 74-79
13 Sah RP, Chari ST. Serologic issues in IgG4-related systemic disease and autoimmune pancreatitis. Current opinion in rheumatology 2011; 23: 108-113
14 Kamisawa T, Shimosegawa T, Okazaki K et al. Standard steroid treatment for autoimmune pancreatitis. Gut 2009; 58: 1504-1507
15 Nishimori I, Tamakoshi A, Otsuki M. Prevalence of autoimmune pancreatitis in Japan from a nationwide survey in 2002. Journal of gastroenterology 2007; 42 (Suppl. 18) 6-8
16 Nirula A, Glaser SM, Kalled SL et al. What is IgG4? A review of the biology of a unique immunoglobulin subtype. Current opinion in rheumatology 2011; 23: 119-124
17 Zen Y, Nakanuma Y. Pathogenesis of IgG4-related disease. Current opinion in rheumatology 2011; 23: 114-118
18 Ferrari S, Mudde GC, Rieger M et al. IgG subclass distribution of anti-ADAMTS13 antibodies in patients with acquired thrombotic thrombocytopenic purpura. Journal of thrombosis and haemostasis: JTH 2009; 7: 1703-1710
19 Stone JH, Zen Y, Deshpande V. IgG4-related disease. The New England journal of medicine 2012; 366: 539-551
20 Kawa S, Ota M, Yoshizawa K et al. HLA DRB10405-DQB10401 haplotype is associated with autoimmune pancreatitis in the Japanese population. Gastroenterology 2002; 122: 1264-1269
21 Scalapino KJ, Daikh DI. CTLA-4: a key regulatory point in the control of autoimmune disease. Immunological reviews 2008; 223: 143-155
22 Chang MC, Chang YT, Tien YW et al. T-cell regulatory gene CTLA-4 polymorphism/haplotype association with autoimmune pancreatitis. Clinical chemistry 2007; 53: 1700-1705
23 Umemura T, Ota M, Hamano H et al. Genetic association of Fc receptor-like 3 polymorphisms with autoimmune pancreatitis in Japanese patients. Gut 2006; 55: 1367-1368
24 Taniguchi T, Ko M, Seko S et al. Interstitial pneumonia associated with autoimmune pancreatitis. Gut 2004; 53: 770 author reply 770-771
25 Duvic C, Desrame J, Leveque C et al. Retroperitoneal fibrosis, sclerosing pancreatitis and bronchiolitis obliterans with organizing pneumonia. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association – European Renal Association 2004; 19: 2397-2399
26 Fujinaga Y, Kadoya M, Kawa S et al. Characteristic findings in images of extra-pancreatic lesions associated with autoimmune pancreatitis. European journal of radiology 2010; 76: 228-238
27 Inoue D, Zen Y, Abo H et al. Immunoglobulin G4-related lung disease: CT findings with pathologic correlations. Radiology 2009; 251: 260-270
28 Zen Y, Inoue D, Kitao A et al. IgG4-related lung and pleural disease: a clinicopathologic study of 21 cases. The American journal of surgical pathology 2009; 33: 1886-1893
29 Ryu JH, Sekiguchi H, Yi ES. Pulmonary manifestations of immunoglobulin G4-related sclerosing disease. The European respiratory journal: official journal of the European Society for Clinical Respiratory Physiology 2012; 39: 180-186
30 Naitoh I, Nakazawa T, Ohara H et al. Clinical significance of extrapancreatic lesions in autoimmune pancreatitis. Pancreas 2010; 39: e1-e5
31 Hamano H, Arakura N, Muraki T et al. Prevalence and distribution of extrapancreatic lesions complicating autoimmune pancreatitis. Journal of gastroenterology 2006; 41: 1197-1205
32 Tsushima K, Tanabe T, Yamamoto H et al. Pulmonary involvement of autoimmune pancreatitis. European journal of clinical investigation 2009; 39: 714-722
33 Cheuk W, Yuen HK, Chu SY et al. Lymphadenopathy of IgG4-related sclerosing disease. The American journal of surgical pathology 2008; 32: 671-681
34 Nakajo M, Jinnouchi S, Fukukura Y et al. The efficacy of whole-body FDG-PET or PET/CT for autoimmune pancreatitis and associated extrapancreatic autoimmune lesions. European journal of nuclear medicine and molecular imaging 2007; 34: 2088-2095
35 Inoue M, Nose N, Nishikawa H et al. Successful treatment of sclerosing mediastinitis with a high serum IgG4 level. General thoracic and cardiovascular surgery 2007; 55: 431-433
36 Yamashita K, Haga H, Kobashi Y et al. Lung involvement in IgG4-related lymphoplasmacytic vasculitis and interstitial fibrosis: report of 3 cases and review of the literature. The American journal of surgical pathology 2008; 32: 1620-1626
37 Ohara H, Nakazawa T, Sano H et al. Systemic extrapancreatic lesions associated with autoimmune pancreatitis. Pancreas 2005; 31: 232-237
38 Hirano K, Kawabe T, Komatsu Y et al. High-rate pulmonary involvement in autoimmune pancreatitis. Internal medicine journal 2006; 36: 58-61
39 Zen Y, Kitagawa S, Minato H et al. IgG4-positive plasma cells in inflammatory pseudotumor (plasma cell granuloma) of the lung. Human pathology 2005; 36: 710-717
40 Taniguchi T, Hamasaki A, Okamoto M. A case of suspected lymphocytic hypophysitis and organizing pneumonia during maintenance therapy for autoimmune pancreatitis associated with autoimmune thrombocytopenia. Endocrine journal 2006; 53: 563-566
41 Takato H, Yasui M, Ichikawa Y et al. Nonspecific interstitial pneumonia with abundant IgG4-positive cells infiltration, which was thought as pulmonary involvement of IgG4-related autoimmune disease. Intern Med 2008; 47: 291-294
42 Shrestha B, Sekiguchi H, Colby TV et al. Distinctive pulmonary histopathology with increased IgG4-positive plasma cells in patients with autoimmune pancreatitis: report of 6 and 12 cases with similar histopathology. The American journal of surgical pathology 2009; 33: 1450-1462
43 Ito M, Yasuo M, Yamamoto H et al. Central airway stenosis in a patient with autoimmune pancreatitis. The European respiratory journal: official journal of the European Society for Clinical Respiratory Physiology 2009; 33: 680-683
44 Nguyen VX, De Petris G, Nguyen BD. Usefulness of PET/CT imaging in systemic IgG4-related sclerosing disease. A report of three cases. JOP: Journal of the pancreas 2011; 12: 297-305
45 Umehara H, Okazaki K, Masaki Y et al. A novel clinical entity, IgG4-related disease (IgG4RD): general concept and details. Modern rheumatology/ the Japan Rheumatism Association 2011;
46 Masaki Y, Sugai S, Umehara H. IgG4-related diseases including Mikulicz's disease and sclerosing pancreatitis: diagnostic insights. The Journal of rheumatology 2010; 37: 1380-1385
47 Kawano M, Saeki T, Nakashima H et al. Proposal for diagnostic criteria for IgG4-related kidney disease. Clinical and experimental nephrology 2011; 15: 615-626
48 Okazaki K, Kawa S, Kamisawa T et al. Clinical diagnostic criteria of autoimmune pancreatitis: revised proposal. Journal of gastroenterology 2006; 41: 626-631
49 Umehara H, Okazaki K, Masaki Y et al. Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011. Modern rheumatology/the Japan Rheumatism Association 2012;
50 Cheuk W, Chan JK. IgG4-related sclerosing disease: a critical appraisal of an evolving clinicopathologic entity. Advances in anatomic pathology 2010; 17: 303-332
51 Kamisawa T, Yoshiike M, Egawa N et al. Treating patients with autoimmune pancreatitis: results from a long-term follow-up study. Pancreatology 2005; 5: 234-238 discussion 238-240
52 Church NI, Pereira SP, Deheragoda MG et al. Autoimmune pancreatitis: clinical and radiological features and objective response to steroid therapy in a UK series. The American journal of gastroenterology 2007; 102: 2417-2425
53 Naitoh I, Nakazawa T, Ohara H et al. Autoimmune pancreatitis associated with various extrapancreatic lesions during a long-term clinical course successfully treated with azathioprine and corticosteroid maintenance therapy. Intern Med 2009; 48: 2003-2007
54 Matsushita M, Ikeura T, Fukui T et al. Refractory autoimmune pancreatitis: azathioprine or steroid pulse therapy?. The American journal of gastroenterology 2008; 103: 1834 author reply 1834-1835
55 Khan ML, Colby TV, Viggiano RW et al. Treatment with bortezomib of a patient having hyper IgG4 disease. Clinical lymphoma, myeloma & leukemia 2010; 10: 217-219
56 Ghazale A, Chari ST, Zhang L et al. Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. Gastroenterology 2008; 134: 706-715
57 Khosroshahi A, Bloch DB, Deshpande V et al. Rituximab therapy leads to rapid decline of serum IgG4 levels and prompt clinical improvement in IgG4-related systemic disease. Arthritis and rheumatism 2010; 62: 1755-1762
58 Manz RA, Hauser AE, Hiepe F et al. Maintenance of serum antibody levels. Annual review of immunology 2005; 23: 367-386
59 Neubert K, Meister S, Moser K et al. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nature medicine 2008; 14: 748-755
60 Takahashi N, Ghazale AH, Smyrk TC et al. Possible association between IgG4-associated systemic disease with or without autoimmune pancreatitis and non-Hodgkin lymphoma. Pancreas 2009; 38: 523-526
61 Fukui T, Mitsuyama T, Takaoka M et al. Pancreatic cancer associated with autoimmune pancreatitis in remission. Intern Med 2008; 47: 151-155